Adjuvant treatment of breast cancer with taxanes

Breast Care

Volumn 1, Issue 3, 2006, Pages 171-175

  Wenzel, Catharina ^a   Steger, Günther G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Breast cancer; Chemotherapy, adjuvant; Docetaxel; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; VINCRISTINE;

AMENORRHEA; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER PREVENTION; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SCREENING; DRUG USE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HUMAN; INFECTION; LYMPH NODE METASTASIS; NEUTROPENIA; POPULATION; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; STANDARD; TREATMENT CONTRAINDICATION;

EID: 33745850820     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000093800     Document Type: Review

References (23)

1. Early Breast Cancer Trialist's Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
2. Early Breast Cancer Trialist's Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717.
3. Levine MN, Bramwell VH, Pritchard KI, et al.: Randomized trial of intensive cyclophophamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-2658.
4. Hutchins L, Green S, Ravdin P, et al.: CMF versus CAF with and without tamoxiten in high-risk node-negative breast cancer patients: first results of intergroup trial INT 0102. Proc Am Soc Clin Oncol 1998;17a:1a (abstr2).
5. Poole CJ, Earl HM, Dunn JA, et al.: NEAT (National Epirubicin Adjuvant Trial), and SCTBG BR9601 (Scottish Cancer Trials Breast Group) phase III adjuvant breast trials show a significant relapse-free and overall survival advantage for sequential ECMF. Proc Am Soc Clin Oncol 2003;22:4 (abstr 13).
6. Bonadonna G, Moliterni A, Zambetti M, et al.: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005;330:217.
7. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581.
8. Seidman AD, Reichman BS, Crown JP, et al.: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-1159.
9. Valero V, Holmes FA, Walters RS, et al.: Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894.
10. Holmes FA, Walters RS, Theriault RL, et al.: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-1805.
11. Nabholtz JM, Senn HJ, Bezwoda WR, et al.: Prospective randomised trial of docetaxel versus mitomycin plus vinblastin in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999;17:1413-1424.
12. Chan S, Friedrichs K, Noel D, et al.: Prospective randomised trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
13. Sledge GW, Neuberg D, Bernardo P, et al.: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588-592.
14. Nabholtz JM, Falkson C, Campos D, et al.: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase II trial. J Clin Oncol 2003;21:968-975.
15. Biganzoli L, Cufer T, Bruning P, et al.: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase II trial. J Clin Oncol 2002;20:3114-3121.
16. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
17. Smith IC, Heys SD, Hutcheon AW, et al.: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002;20:1456-1466.
18. Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, Wickerham DL, Yothers G, Soran A, Wolmark N: Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-3696.
19. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei III E, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
20. Martin M, Pienkowski T, Mackey J, et al.: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
21. Roche H, Fumoleau P, Spielmann M, et al.: 6 cycles of FEC 100 vs. 3 FEC 100 followed by 3 cycles of docetaxel for node-positive breast cancer patients: analysis at 5 years of the adjuvant PACS 01 trial. SABCS 2005;27a:27(abstr).
22. Citron ML, Berry DA, Cirrincione C, et al.: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C 9741 / Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
23. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ, and panel members: Meeting highlights: International Expert Consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.